NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Determining Risk in Latent Tuberculosis

Terminated

Conditions: Latent Tuberculosis

First Posted Date: 2012-04-05

Last Posted Date: 2019-11-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 18

Registration Number: NCT01571739

Locations: 🇰🇷
National Medical Center, Seoul, Korea, Republic of

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: PA-824
Drug: Lopinavir/Ritonavir (LPV/r)
Drug: Efavirenz (EFV)
Drug: Rifampin (RIF)

First Posted Date: 2012-04-05

Last Posted Date: 2021-11-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 52

Registration Number: NCT01571414

Locations: 🇺🇸
Ucsf Hiv/Aids Crs, San Francisco, California, United States
🇺🇸
Johns Hopkins University CRS, Baltimore, Maryland, United States
🇺🇸
Ohio State University CRS, Columbus, Ohio, United States

and more 1 locations

CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")

Phase 4

Completed

Conditions: Cytomegalovirus Infection

Interventions: Drug: Valganciclovir

First Posted Date: 2012-03-13

Last Posted Date: 2021-08-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 205

Registration Number: NCT01552369

Locations: 🇺🇸
Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
Mayo Clinic, Rochester - Infectious Diseases, Rochester, Minnesota, United States
🇺🇸
Emory Clinic - Transplant Center, Atlanta, Georgia, United States

and more 3 locations

Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome

Phase 2

Terminated

Conditions: Primary Sjögren's Syndrome

Interventions: Other: Placebo
Biological: Baminercept

First Posted Date: 2012-03-13

Last Posted Date: 2019-01-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 52

Registration Number: NCT01552681

Locations: 🇺🇸
St. Francis Hospital and Medical Center, Hartford, Connecticut, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States

and more 6 locations

Phase I Trial of a Single Dose of CRS3123

Phase 1

Completed

Conditions: Clostridium Difficile Colitis

Interventions: Drug: CRS3123
Other: Placebo

First Posted Date: 2012-03-12

Last Posted Date: 2017-09-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT01551004

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center - Infectious Diseases, Baltimore, Maryland, United States

Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: VRC-HIVDNA009-00-VP
Biological: Placebo vaccine

First Posted Date: 2012-03-09

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 31

Registration Number: NCT01549470

Locations: 🇺🇬
Makerere University Walter Reed Project (MUWRP), Kampala, Uganda

Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: VRC-HIVADV014-00-VP Vaccine

First Posted Date: 2012-03-09

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 18

Registration Number: NCT01549509

Locations: 🇺🇬
Makerere University Walter Reed Project (MUWRP), Kampala, Uganda

Effect of Filarial Infection on Immune Responses in Latent Tuberculosis

Completed

Conditions: Tuberculosis
Filariasis
Mycobacterium Infections
Latent Tuberculosis

First Posted Date: 2012-03-08

Last Posted Date: 2021-04-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 4268

Registration Number: NCT01547884

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi, Bethesda, Maryland, United States
🇮🇳
Nih-Nirt Icer, Chennai, India

Sanaria™ PfSPZ Challenge Vaccine

Phase 1

Completed

Conditions: Malaria

Interventions: Biological: Sanaria™ PfSPZ Vaccine
Drug: Chloroquine

First Posted Date: 2012-03-07

Last Posted Date: 2013-09-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT01546389

Locations: 🇺🇸
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States

Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Influenza A Subtype H7N7 Infection

Interventions: Biological: Monovalent Influenza Subvirion Vaccine, H7N7

First Posted Date: 2012-02-16

Last Posted Date: 2015-12-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 45

Registration Number: NCT01534468

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy